0001193125-12-303459.txt : 20120716 0001193125-12-303459.hdr.sgml : 20120716 20120716162024 ACCESSION NUMBER: 0001193125-12-303459 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120710 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20120716 DATE AS OF CHANGE: 20120716 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OXIGENE INC CENTRAL INDEX KEY: 0000908259 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 133679168 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21990 FILM NUMBER: 12963970 BUSINESS ADDRESS: STREET 1: 701 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-635-7000 MAIL ADDRESS: STREET 1: 701 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 d381008d8k.htm 8-K 8-K

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 10, 2012

OXiGENE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   0-21990   13-3679168
(State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

701 Gateway Boulevard, Suite 210, South San Francisco, CA 94080

(Address of principal executive offices)

Registrant’s telephone number, including area code: (650) 635-7000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(a), (d), and (f) Not applicable.

(b), (c), and (e) On July 10, 2012, David L. Johnson notified OXiGENE, Inc. (the “Company”) of his intent to resign from his position as part-time Chief Financial Officer and principal accounting officer of the Company, effective not later than July 30, 2012, to pursue other interests.

The Company has begun a search for a permanent replacement for Mr. Johnson and intends to use an external search firm to assist in identifying qualified candidates. In the interim, the duties of the principal financial officer will be performed by Barbara Riching, Director of Finance of the Company.

Ms. Riching, age 53, has many years of experience in the life sciences industry and is a Certified Public Accountant. Ms. Riching joined the Company in December 2011. Previously, she had served as the Senior Director of Finance for Abgenix, Inc. from 1999 until 2005, just prior to its acquisition by Amgen Inc. Prior to Abgenix, Ms. Riching worked in finance positions at ALZA Corporation, Natural Wonders, Inc., and Ernst & Young LLP. She holds a B.A. degree from the University of California at Santa Barbara. Ms. Riching will be paid $165 per hour for her service in this interim capacity. Ms. Riching is also a party to the Company’s standard form of employee proprietary information and inventions agreements and to an indemnification agreement with the Company.

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 16, 2012

OXIGENE, INC.
/s/ Peter J. Langecker

By: Peter J. Langecker

Chief Executive Officer